According to a new report, published by KBV research, The Global Narcolepsy Therapeutics Market size is expected to reach $5 billion by 2028, rising at a market growth of 10.5% CAGR during the forecast period.
The Narcolepsy without Cataplexy segment is showcasing a CAGR of 10.6% during (2022 - 2028). It is due to the rise in public knowledge brought on by awareness initiatives run by several networks, including the U.S. Narcolepsy Network and the Europe Narcolepsy Network. EDS is frequently the initial clinically noticeable sign. The most frequent cause of EDS in the United States, according to the National Institute of Neurological Disorders and Stroke, is sleep deprivation.
The Sodium Oxybate segment acquired maximum revenue share in the Global Narcolepsy Therapeutics Market by Product in 2021 thereby, achieving a market value of $2.1 billion by 2028. Due to the expensive price of this drug, the existence of favorable reimbursement policies, and the expanding levels of knowledge regarding diagnosis & related treatments. The FDA-approved medicine in this class, Xyrem, has a high prescription rate because it is specifically intended for use in treating cataplexy and its accompanying EDS.
The Europe market dominated the Global Narcolepsy Therapeutics Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1.6 billion by 2028. The North America market is exhibiting a CAGR of 9.8% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 11.4% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/narcolepsy-therapeutics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.
By Type
By Product
By Geography
Companies Profiled
Unique Offerings 
